🇺🇸United States
Overcharging MTM Services Beyond State-Regulated Amounts
1 verified sources
Definition
Pharmacies charging SeniorCare members more than remittance-specified amounts for MTM services violate state statutes, requiring mandatory refunds and risking penalties. Providers must track spenddown/deductible status precisely, but failures lead to overcharges and refund obligations. Systemic compliance demands real-time eligibility verification to avoid legal repercussions.
Key Findings
- Financial Impact: Refunds plus potential fines under Wis. Stat. § 49.688(5)(a)
- Frequency: Per overcharged claim - recurring until eligibility systems improved
- Root Cause: Inadequate real-time access to member spenddown/deductible data from payers
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Retail Pharmacies.
Affected Stakeholders
frontline pharmacists, billing teams, pharmacy owners
Action Plan
Run AI-powered research on this problem. Each action generates a detailed report with sources.
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Related Business Risks
Medicare Fraud Risk from Unbilled Parallel MTM Services
Full service value plus fraud penalties/repayments
Incorrect MTM Billing Codes Leading to Zero Reimbursement
$34-$130 per unbilled unit (based on service level rates)
Denied MTM Claims Due to New vs Established Patient Coding Errors
$52-$148 per denied CMR/A service
HRSA Audit Failures and Required Repayments for Diversion/Duplicate Discounts
$Repayment of full discounts plus potential civil monetary penalties per audit
Excess Labor and Overtime from Manual Compliance and Documentation Tasks
$1,000–$6,000 per store per month in additional labor and overtime associated with controlled‑substance record‑keeping and reconciliation
Delayed Reimbursement from Holds and Rejections on Controlled Substance Claims
$500–$4,000 per store per month in financing cost of delayed cash and staff time for claims follow‑up related to controlled substances